Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pathogen inactivation trial suspended

This article was originally published in The Gray Sheet

Executive Summary

Vitex "temporarily" halts patient enrollment in a Phase III study exploring use of its Inactine pathogen inactivation system with red blood cells for an acute-only indication. The decision to suspend enrollment comes a little over a month after a data safety monitoring board cleared the trial despite antibody problems found in Vitex' earlier Phase III trial, which supported a chronic infusion claim (1"The Gray Sheet" Oct. 18, 2004, In Brief). The latter trial was halted a year ago. The acute-only study was suspended because of one patient's immune response to Inactine-treated red cells, Vitex says. Antibody issues also have posed hurdles to clinical development of Baxter/Cerus' Intercept...

You may also be interested in...

Biotechnology News In Brief

Ovarian cancer test study: Four-analyte blood test developed by researchers at the Nevada Cancer Institute and Yale University School of Medicine requires "further improvement" before it is to be recommended for population screening of ovarian cancer, they note in the May 10 Proceedings of the National Academy of Sciences. The assay demonstrated 95% sensitivity and 95% specificity in a blinded cross-validation study involving 106 healthy females and 100 patients with epithelial ovarian cancer (EOC). Nevertheless, the study authors cite 99.6% as a desirable threshold for specificity. They advise that "other proteins previously implicated in EOC discrimination" might enhance the assay, which could be offered to high-risk patients. Follow-up evaluations such as transvaginal ultrasound then could be conducted in patients who test positive twice, the researchers note. The test used ELISA and microarray screening analysis, performed by Qiagen...

Vitex R&D, business developments

Data safety monitoring board clears manufacturer to continue Phase III trial of Inactine pathogen inactivation system to treat red blood cells under an acute-only indication. In 2003, the firm stopped a Phase III trial in red blood cells that supported a chronic transfusion claim, citing problems with antibody formation in sickle cell anemia patients. The firm is seeking shareholder approval for a merger agreement with Panacos Pharmaceuticals...

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts